Here are the 424B prospectus supplements from MINDMAZE THRAPEUTICS HLDS (RLFTF) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RLFTF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLFTF filings page.
MindMaze Therapeutics Holding files a Form F-6/Fractional ADR form reflecting its name change to MindMaze Therapeutics Holding effective December 1, 2025 and updates the depositary's address to 270 Park Avenue, Floor 8, New York, NY 10017. The form specifies that each ADS represents one (1) ordinary share with a nominal value of CHF 0.10, summarizes issuance, withdrawal, voting, tax and fee mechanics for ADS holders, and describes nominee, disclosure and termination provisions governing the ADR program.